Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618 28. 871. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation. 2002;106:2404 8. 872. Azevedo ER, Schofield AM, Kelly S, et al. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol. 2001;37:505 9. 873. Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol. 1998;31:83 8. 874. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049 57. 875. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemo- dynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26: 1575 80. 876. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989;13: 786 95. 877. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993;72:1249 56. 878. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation. 1995;91:1368 74. 879. Abrams J. Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration. Drugs. 1987;34:391 403. 880. Iafrate RP Jr, Yost RL, Curry SH, et al. Effect of dose and ointment application technique on nitroglycerin plasma concentrations. Pharma- cotherapy. 1983;3:118 24. 881. Moe G, Armstrong PW. Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. Am J Med. 1986; 81:765 70. 882. 